The effect of oral cotrimoxazole and topical intranasal mupirucin on staphylococcus aureus colonization in hemodialysis patients

Comparison of the effect of oral cotrimoxazole and topical intranasal mupirucin on staphylococcus aureus colonization in hemodialysis patients: A clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016122331527N1

Enrollment

Registered

2017-02-17

Start date

2017-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients. Extracorporeal dialysis

Interventions

Intervention 1: Intevention group: Oral cotrimoxazole 400 mg twice daily for 7 days. Intervention 2: Control group: Topical mupirocin 2% twice daily for 5 days.

Treatment - Drugs

Intevention group: Oral cotrimoxazole 400 mg twice daily for 7 days

Control group: Topical mupirocin 2% twice daily for 5 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria : Hemodialysis patients carriers of staphylococcus. Exclusion criteria:Patients death; patients migration

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bacterial decolonization. Timepoint: 1,4 and 12 weeks after treatment. Method of measurement: Bacterial culture.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojgan Taleb

Imam Hossein Hospital, Shahroud University of Medical Sciences

binesh@shmu.ac.ir+98 23 3234 2001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026